Technical Analysis for FUSN - Fusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 12.36 0.16% 0.02
FUSN closed up 0.16 percent on Friday, October 23, 2020, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical FUSN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
NR7 Range Contraction 0.16%
NR7-2 Range Contraction 0.16%
Fell Below 50 DMA Bearish -1.36%
NR7 Range Contraction -1.36%
Inside Day Range Contraction -1.36%
Crossed Above 20 DMA Bullish -2.06%
Older End-of-Day Gignals for FUSN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Solid Tumors Antibodies Cell Biology Tumors Tyrosine Kinase Receptors Proteins Radiopharmaceuticals Pharmacodynamics Fibroblast Growth Factor Growth Factor

Is FUSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.0
52 Week Low 11.5
Average Volume 41,861
200-Day Moving Average 0.00
50-Day Moving Average 12.50
20-Day Moving Average 12.20
10-Day Moving Average 12.54
Average True Range 0.55
ADX 30.87
+DI 11.03
-DI 17.38
Chandelier Exit (Long, 3 ATRs ) 11.48
Chandelier Exit (Short, 3 ATRs ) 13.14
Upper Bollinger Band 13.00
Lower Bollinger Band 11.41
Percent B (%b) 0.6
BandWidth 13.00
MACD Line -0.01
MACD Signal Line -0.07
MACD Histogram 0.0529
Fundamentals Value
Market Cap 514.97 Million
Num Shares 41.7 Million
EPS -0.57
Price-to-Earnings (P/E) Ratio -21.58
Price-to-Sales 0.00
Price-to-Book 1.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.75
Resistance 3 (R3) 12.75 12.61 12.69
Resistance 2 (R2) 12.61 12.51 12.62 12.66
Resistance 1 (R1) 12.49 12.45 12.55 12.49 12.64
Pivot Point 12.35 12.35 12.39 12.36 12.35
Support 1 (S1) 12.23 12.25 12.29 12.23 12.08
Support 2 (S2) 12.09 12.19 12.10 12.06
Support 3 (S3) 11.97 12.09 12.04
Support 4 (S4) 11.97